Glutamine

Glutamine

SCHEMBL4989095

NC(=O)CCC(N)C(=O)O.c1ccc2c(c1)C2

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.66
ALOX15 P16050 1/20 0.66
BLM P54132 1/20 0.66
PMP22 Q01453 1/20 0.66
LTA4H P09960 2/20 0.49
KIF11 P52732 4/20 0.47
SLC1A3 P43003 2/20 0.47
SLC1A2 P43004 2/20 0.47
SLC1A1 P43005 2/20 0.47
GRM8 O00222 1/20 0.47
GRM6 O15303 1/20 0.47
GRIN2D O15399 1/20 0.47
GRIN3B O60391 1/20 0.47
GSR P00390 1/20 0.47
CYP1A2 P05177 1/20 0.47
GRIK1 P39086 1/20 0.47
GRM5 P41594 1/20 0.47
GRIA1 P42261 1/20 0.47
GRIA2 P42262 1/20 0.47
GRIA3 P42263 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutamine SCHEMBL8630970 0.98 KMT2A (0.63) KMT2AALOX15BLMPMP22LTA4H
D-Glutamate SCHEMBL561574 0.88 SLC1A3 (0.64) KMT2AALOX15BLMPMP22LTA4H
Biphenyl SCHEMBL8982408 0.86 KMT2A (0.70) KMT2AALOX15BLMPMP22LTA4H
Biphenyl SCHEMBL8982412 0.86 KMT2A (0.70) KMT2AALOX15BLMPMP22LTA4H
Glutamine SCHEMBL28281766 0.85 ALOX15 (0.91) KMT2AALOX15BLMPMP22LTA4H
SCHEMBL8618296 0.85 KMT2A (0.48) KMT2AALOX15BLMPMP22LTA4H
Homoserine SCHEMBL6051437 0.84 KIF11 (0.49) KMT2AALOX15BLMPMP22LTA4H
Glutamine SCHEMBL15269081 0.84 KMT2A (0.68) KMT2AALOX15BLMPMP22LTA4H
Glutamine SCHEMBL15269077 0.84 KMT2A (0.68) KMT2AALOX15BLMPMP22LTA4H
Glutamine SCHEMBL7902170 0.83 ALOX15 (0.66) KMT2AALOX15BLMPMP22LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240065990-A1 METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID BELLUS HEALTH INC (CA) 2024-02-29 US claimed
EP-3851447-B1 METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID BELLUS HEALTH INC (CA) 2023-09-06 EP claimed
EP-3851447-A1 METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID BHI Limited Partnership (CA) 2021-07-21 EP claimed
US-20080146642-A1 Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease BELLUS HEALTH INC. (CA) 2008-06-19 US claimed
CN-119751538-A Medicine for removing fat or fat pad and application 西安莱格瑞生物科技有限公司 2025-04-04 CN disclosed
CN-117815245-A Medicine for removing fat or fat pad and application 西安莱格瑞生物科技有限公司 2024-04-05 CN disclosed
US-20240065990-A1 METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID BELLUS HEALTH INC (CA) 2024-02-29 US disclosed
EP-4289820-A2 COMPOUNDS FOR USE IN TREATING ALZHEIMER'S DISEASE IN APOE4+/+ PATIENTS Alzheon, Inc. (US) 2023-12-13 EP disclosed
EP-3851447-B1 METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID BELLUS HEALTH INC (CA) 2023-09-06 EP disclosed
EP-3119911-B1 COMPOUNDS FOR USE IN TREATING ALZHEIMER'S DISEASE IN APOE4+/+ PATIENTS ALZHEON INC (US) 2023-08-09 EP disclosed
US-20230087041-A1 METHODS FOR TREATING NEUROLOGICAL DISORDERS ALZHEON, INC. 2023-03-23 US disclosed
US-20210386693-A1 METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2021-12-16 US disclosed
EP-3119911-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS Alzheon, Inc. (US) 2017-01-25 EP disclosed
US-9499480-B2 Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid BHI LIMITED PARTNERSHIP (CA) 2016-11-22 US disclosed
WO-2015143447-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS ALZHEON, INC. (US) 2015-09-24 WO disclosed
EP-2862581-A2 Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid BHI Limited Partnership (CA) 2015-04-22 EP disclosed
EP-2089417-B1 METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID BHI LTD PARTNERSHIP (CA) 2014-12-31 EP disclosed
US-20140220122-A1 METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID BHI LIMITED PARTNERSHIP (CA) 2014-08-07 US disclosed
US-8748656-B2 Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid BHI LIMITED PARTNERSHIP (CA) 2014-06-10 US disclosed
US-20080146642-A1 Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease BELLUS HEALTH INC. (CA) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240065990-A1 METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID APP, PSEN1, PSEN2 KMT2A 3091/4885ALOX15 1882/4885BLM 4527/4885
US-20210386693-A1 METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID APP, PSEN1, PSEN2 KMT2A 3162/4885ALOX15 1998/4885BLM 4559/4885
US-20230087041-A1 METHODS FOR TREATING NEUROLOGICAL DISORDERS ACHE, PSEN2, PSEN1 KMT2A 1777/4885ALOX15 676/4885BLM 2367/4885
US-20080146642-A1 Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease DNPEP, DAO, APP KMT2A 2014/4885ALOX15 1144/4885BLM 4691/4885
US-20140220122-A1 METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID APP, PSEN1, PSEN2 KMT2A 3162/4885ALOX15 1998/4885BLM 4559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.